Hyperandrogenism and skin: polycystic ovary syndrome and peripheral insulin resistance by Yarak, Samira et al.
Received on May 31, 2005.
Approved by the Consultive Council and accepted for publication on July 04, 2005. 
* Work done at Universidade Federal de São Paulo - Escola Paulista de Medicina (Unifesp - EPM) - São Paulo (SP), Brazil.
1 Commissioned physician, Department of Dermatology. Master's degree in Dermatology from Universidade Federal de São Paulo - Escola Paulista de Medicina (Unifesp-EPM) - 
São Paulo (SP), Brazil.
2 Physician, Department of Dermatology. Ph.D. degree in Dermatology from Universidade Federal de São Paulo - Escola Paulista de Medicina (Unifesp - EPM) - São Paulo (SP), Brazil.
3 Physician, Department of Dermatology. Master's degree in Dermatology from Universidade Federal de São Paulo - Escola Paulista de Medicina (Unifesp - EPM) - São Paulo (SP), Brazil.
4 Volunteer physician, Department of Dermatology, Universidade Federal de São Paulo - Escola Paulista de Medicina (Unifesp - EPM) - São Paulo (SP), Brazil.
5 Adjunct Professor, Department of Dermatology, Master's degree in Dermatology from Universidade Federal de São Paulo - Escola Paulista de Medicina (Unifesp - EPM) - São 
Paulo (SP), Brazil.
©2005 by Anais Brasileiros de Dermatologia
Hyperandrogenism and skin: polycystic ovary syndrome and
peripheral insulin resistance*
Hiperandrogenismo e pele: síndrome do ovário policístico e 
resistência periférica à insulina*
Samira Yarak1 Ediléia Bagatin2 Karime Marques Hassun3
Meire Odete Américo Brasil Parada4 Sérgio Talarico Filho5
395
An Bras Dermatol. 2005; 80(4):395-410.
Review Article
Abstract: The polycystic ovary syndrome is an extremely common endocrine disorder in women of
chilbearing age. It is characterized by menstrual disturbance, hyperandrogenism and/or
hyperandrogenemia. The primary pathophysiological defect is unknown, but important characteristics
include insulin resistance, androgen excess and impaired gonadotropin dynamics. The most
frequent clinical characteristics of polycystic ovary syndrome are associated with the pilosebaceous
unit, such as hirsutism, acne, seborrhea and alopecia. Thus, the dermatologist may be responsible
for making an early diagnosis of the syndrome, thus preventing delay in establishing preventive and
therapeutic measures. The current management recommended for skin manifestations of polycystic
ovary syndrome includes combined oral contraceptives, antiandrogens and insulin-sensitizing
agents, besides changes in life style. This is a review article on diagnosis, pathophysiology and treat-
ment of polycystic ovary syndrome. The authors emphasize that a clear understanding of patho-
physiology of this syndrome, especially by dermatologists, is crucial for its preventive treatment
through the different phases in the life of women. 
Keywords: Hyperandrogenism / diagnosis; Hyperandrogenism / therapy; Skin; Insulin resistance;
Hypothalamic-pituitary axis; Treatment
Resumo: A síndrome do ovário policístico é distúrbio endócrino feminino, extremamente comum
na idade reprodutiva. Caracteriza-se por anormalidades menstruais, hiperandrogenismo e/ou
hiperandrogenemia. A principal alteração na fisiopatologia é desconhecida. Entretanto, parece
que a resistência à insulina, o hiperandrogenismo e a alteração na dinâmica das gonadotropinas
são os mais importantes mecanismos fisiopatológicos envolvidos. As características clínicas mais
freqüentes da síndrome do ovário policístico estão relacionadas com a unidade pilossebácea,
como hirsutismo, acne, seborréia e alopecia. Desse modo, o dermatologista pode ser responsável
pelo diagnóstico precoce da síndrome, evitando o retardo na instituição de medidas terapêutico-
preventivas. Atualmente, as drogas recomendadas para as manifestações cutâneas da síndrome
do ovário policístico são os contraceptivos orais conjugados, antiandrógenos e sensibilizantes de
insulina e, além disso, é geralmente recomendada a modificação no estilo de vida. Trata-se de
artigo de revisão sobre diagnóstico, fisiopatologia e tratamento da síndrome do ovário policísti-
co. Os autores enfatizam que o conhecimento da fisiopatologia dessa síndrome, principalmente
pelos dermatologistas, é fundamental para seu tratamento preventivo, nas diferentes fases da
vida da mulher. 
Palavras-chave: Hiperandrogenismo / diagnóstico; Hiperandrogenismo / terapia; Pele; Resistência
à insulina; Sistema hipotálamo-hipofisário
INTRODUCTION
Hyperandrogenism is a term used to describe
the clinical signs related to the biological action of
androgens.1-3 Hyperandrogenemia or biochemical
hyperandrogenism means increased blood androgen
levels.2 The maximum clinical expression of hyperan-
drogenism is  virilization.2 Idiopathic hyperandroge-
nism is characterized by clinical expression and no
biochemical alterations, whereas occult hyperandro-
genism is characterized by no clinical expression and
presence of biochemical changes.2
Hyperandrogenism leads to clinical pictures of
variable severity in females, including early puberty,
hirsutism, acne, seborrhea, alopecia, menstrual distur-
bance and ovulatory dysfunction with infertility dur-
ing reproductive life, metabolic syndrome, psycholo-
gical disorders and virilization.1,2,4 The intensity and
extension of these clinical manifestations depend on
several factors,* and there is no strict correlation bet-
ween intensity of clinical picture and biochemical
alterations.2-4
Several etiologies may cause hyperandrogenism
in women, ranging from hormone disorders2,5 in the
ovaries and adrenal glands (polycystic ovary syndrome
- PCOS and non-classical congenital adrenal hyperpla-
sia - NCCAH) to ovarian or adrenal cancer.2
The main form of hyperandrogenism in females
is functional ovarian or PCOS,6-9 which accounts for
two-thirds of  hyperandrogenic women,2,6 and appro-
ximately 50% of PCOS cases present functional adre-
nal hyperandrogenism.2,4,9
PCOS has a very heterogeneous clinical pic-
ture4,6-9 and is the most common endocrinopathy in
women of childbearing age,10 with a prevalence of
6% to 10%.6,11,12 It is characterized by clinical and/or
biochemical hyperandrogenism and menstrual irre-
gularities,10 and it is probably the most frequent
cause of hirsutism and infertility.6 The etiopathoge-
nesis is still unknown,7,11 although several associa-
tions with biochemical abnormalities have been
described.6,7,13
Stein, Leventhal14 were the first investigators to
identify the association of enlarged  and polycystic
ovaries and amenorrhea, hirsutism and obesity.
PCOS was associated with  adrenal hyperplasia8,15
and, later, with hyperinsulinemia,16 thus demonstra-
ting its metabolic and reproductive effects. Other
investigators17-19 observed later that the defect was in
insulin receptors and obese and non-obese women
presented hyperinsulinemia.20 From then on, the
association between hyperandrogenism, hyperinsu-
linemia21,22 and alterations in serum lipid levels23-25
was given special attention for being able to change
the prognosis of PCOS.23
Many factors contribute to making diagnosis
of PCOS difficult. The National Institute of Child
Health & Human Development (NIHD/NICHD)26
considered the following diagnostic criteria for
PCOS: presence of chronic anovulation, hyperan-
drogenism and/or hyperandrogemia and ruling
out other endocrine diseases with similar pheno-
type. The European Society of Human
Reproduction and Embryology and the American
Society for Reproductive Medicine9 (ESHRE/ASRM)
recommended, apart from ruling out other condi-
tions, the presence of two out of three criteria, as
follows: 1) menstrual dysfunction with oligo-ovu-
lation or anovulation, 2) hyperandrogenism or
hyperandrogenemia and 3) presence or not of
polycystic ovaries. 
In principle, the early diagnosis of PCOS is
important for the possibility of preventing the develop-
ment of some diseases associated with the syndrome.
Thus, dermatologists may be responsible for making
such diagnosis due to the skin manifestations of hyper-
androgenism.   The objective of this review is to provi-
de an update on pathophysiology, diagnosis and treat-
ment of PCOS, considering that, in the past 10 years,
the pathophysiological and therapeutic aspects have
been correlated, particularly regarding peripheral
insulin resistance.
HYPOTHALAMUS-PITUITARY-OVARY-ADRENAL
AXIS - ANDROGEN BIOSYNTHESIS, FACTORS
RELATED TO ITS PRODUCTION AND THE ROLE
OF INSULIN
1. Hypothalamus-pituitary-ovary-adrenal axis  
The hypothalamus and the pituitary gland are
the structures that regulate the endocrine system.5
The sensorial and endocrine information is proces-
sed and integrated in the brain, by means of connec-
tions between the pituitary gland and hypothalamic
or portal system neurons.3,5 In the pituitary anterior
lobe, the portal system produces peptides that bind
to specific cell membrane receptors, thus initiating
hormone release (HR) or inhibition (HI)** (Chart
1).3,5,27,28 The hypothalamus stimulates the production
of gonadotropins in the pituitary through pulsatile
gonadotropin-release hormone (GnRH), increasing
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* Etiology, sex, age, association with other hormone disorders and individual susceptibility factors.2
** Positive and negative feedback mechanisms.
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the transcription of gonadotropin genes (luteinizing
hormone - LH and follicle-stimulating hormone -
FSH) (Figure 1A).27,28 Hence, the frequency of pulsa-
tile GnRH stimulus partly determines the relative
proportion LH and FSH synthesis.27 The increased
frequency of GnRH pulse favors the transcription of
LH  β-subunit over FSH; conversely, decreased GnRH
pulse frequency favors the transcription of FSH β-
subunit, reducing the transcription rate of LH over
FSH.27,28
2. Androgen biosynthesis and factors related to
its production 
The androgens derive from cholesterol and,
in females, are synthetized by the ovaries, adrenal
glands and in extraglandular sites of steroid conver-
sion (liver, muscles, skin and adipose tissue).29,30
Androgen aromatization occurs in muscle and adi-
pose tissues, that is, testosterone (T) and androste-
nedione (A) are converted into estrogens - estrone
and estradiol, whereas, in the pilosebaceous unit
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and skin, T is converted into dihydrotestosterone
(DHT) by the enzyme 5-alpha-reductase 1 or 2
(Figure 1B).29
The pilosebaceous unit and skin represent tar-
get-structures for androgen, which explains the
pathophysiology of hyperandrogenism cutaneous
manifestations (hirsutism, acne, seborrhea and alo-
pecia).2 
3-alpha-androstenediol glucuronide (3α diol
G) derives from the conversion of DHT and A, by
means of 5α-reductase. It is considered a marker of
androgen biological action in the pilosebaceous unit,
and the skin its main production site.2,4,29,30
Androgen  biosynthesis (Figure 2) is mediated
by cytochrome P-450c-17, an enzyme with 17α-hidrox-
ylase, 17, 29-lyase and 17β-hydroxysteroid dehydroge-
nase (17β HSD or 17β R) activities. The androgens (A
and T) are aromatized to estrone by the enzyme aro-
matase (cytochrome p-450 aromatase).27,29,31
In the ovaries, the androgens are precursors of
estrogens and their production is controlled by
Neurohormones Structure Effect Anterior hypophisis Target-tissue
(hypothalamus)
TTRH peptide + TSH Thyroid
PRL Breast
GnRH* peptide + LH, FSH Ovary
PRL (?) Breast (?)
Dopamine amine - LH Ovary
FSH
PRL Breast
TSH Thyroid
CRH peptide + ACTH Adrenal
GHRH peptide + GH Bone
VIP peptide + PRL Breast
Somatostatin peptide - GH Bone
- TSH Thyroid
CHART 1: Hypothalamic neurohormones
Sources: Perez Gutierrez JF et al3, Herman JP et al5
TRH - thyrotropin releasing hormone LH - luteinizing hormone
CRH - corticotropin releasing hormone FSH - follicle stimulating hormone
GnRH - gonadotropin releasing hormone TSH - thyroid stimulating hormone
GHRH - growth hormone releasing hormone PRL - prolactin
VIP - vasoactive intestinal peptide GH - growth hormone
ACTH - adrenocorticotropic hormone
+ = stimulus
- = inhibition
* under physiological conditions or intermittent pulses. The continued use of GnRH inhibits FSH  and LH
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LH/FSH (Figures 1A and 2, and Chart 2).29,30,32 Normal
ovarian function is determined by a combined action
of LH in the theca cells, corpus luteum and stroma,
and of FSH in granulosa cells.28
FSH stimulates the synthesis of estrogens, inhi-
bin, activin and follistatin in granulose cells.33 SHBG,
IGF, inhibin, activin and follistatin release by granulo-
se cells modulate the amount of androgens made in
response to LH.34-36 Insulin and the insulin-like growth
factor (IGF) enhance the action of FSH in granulosa
cells (Figure 1A).13,31,32,34
Eighty percent of circulating T is bound to a
protein produced by the liver - β-globulin (SHBG),
19% is bound to albumin, and only 1% is free and
responsible for the peripheral effect of andro-
gens.3,29,30
Increased levels of β-globulin are related to hig-
her levels of estrogens and thyroid hormones, while
androgens, obesity, glucocorticoids, growth hormone
(GH) and insulin inhibit its synthesis.3,29
Androgen binding to androgen receptors
(AR) is related to DNA, production of mRNA and of
enzyme proteins required for its action (Figure
1B).4,31
3. The role of insulin 
Insulin is a polypeptide secreted by β-cells of
the pancreas, and play an important role in glucose
homeostasis.4,19,31 The classic target tissues include
liver, muscles and adipose tissue. The terms insulin
sensitivity and insulin resistance (IR) refer to the
action of insulin in glucose homeostasis.4,19,31
PATHOPHYSIOLOGY OF THE PCOS
The heterogeneity of PCOS reflects the parti-
cipation of multiple pathophysiological mecha-
nisms (Figure 3); however, how much each mecha-
nism contributes to developing PCOS is still
unknown. 
Biochemical abnormalities13 were described
and it seems that the primary defect is IR in muscles
and adipose tissue, associated with compensatory
adipocytes
leptin
inhibin
inhibin/activin
Follistatin
Insulin
aromatase FT
Te
AR
DHT
activin
A, SDHEA, DHEA
T, A ,SDHEA
ACTH
T1
E
Adrenal
SHBG
H
GHGR
VIP
CGR
GnRH
LH
GH
PRL?
IGF-I
FSH
E
α and β
TGF 
IGF-II
IGFPB-1
Liver
Pancreas
Nucleus
mRNA
DNA
5α
redutase
Peripheral tissue cell
FIGURE 1A AND 1B: Factors involved steroidogenesis regulation and peripheral androgen effect.
FIGURE 1A: Steroidogenesis regulation. FIGURE 1B: Peripheral androgen effect.
PRL - prolactin, TGFα and β - α and β transformation and growth factor, E - estradiol, VIP - vasoactive intestinal peptide, CRH - corti-
cotropin releasing hormone, GHRH - growth hormone releasing hormone, T - testosterone
The liver is the major IGF-1 source, but it is also present in other tissues. GH controls the synthesis of IGF-1
Inhibin and activin belong to the transforming growth factor-beta (TGFbeta) superfamily and modulate the  secretion of FSH.33,34 Inhibin
is a glucoprotein secreted by granulosa cells of the ovarian follicle, placenta and other tissues and it inhibits FSH secretion. Activin is syn-
thesized  by the pituitary and ovarian follicle granulosa cells and it stimulates FSH secretion.35,36 Follistatin is a peptide that binds to
activin, inhibiting its actions34
The peripheral androgen effect depends on the amount of FT, on the activity of 5a-reductase and peripheral androgen receptors (AR)  
The specificity of different tissues to steroidal hormones depends on the presence of specific intracellular protein receptors.3,4
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hyperinsulinemia although the ovaries remain sen-
sitive to insulin.19,37-39 Furthermore, IR may be rela-
ted to an intrinsic dysfunction of pancreatic β-
cells.38
The genetic etiology may be observed in
mothers and sisters of PCOS patients, mainly becau-
se of higher frequency of the syndrome40 and IR,41
Nevertheless, the mode of inheritance remains
uncertain and unknown, as well as the influence of
several environmental factors, such as diet and life
style. 
Another important characteristic in PCOS is
changes in gonadotropin metabolism.4,9 In vivo and in
vitro studies (thecal cell culture) in women with
PCOS suggested that thecal cells are more efficient to
convert androgen precursors into T than normal
cells. The capacity of these cells to increase produc-
tion of androgen is intrinsic and it might be geneti-
cally determined.29,30 Other in vivo studies42,43 obser-
ved abnormalities in the granulose cells of  PCOS
patients.
The theories proposed to explain the
pathophysiology of PCOS could be divided into four
categories:
a) single defect in action and secretion of insu-
lin, causing hyperinsulinemia and IR;
b) primary neuroendocrine defect, leading to
increased pulse frequency and amplitude of LH;
c) defect in androgen synthesis, resulting in
increased production of ovarian androgens; and
d) alteration in cortisol metabolism, resulting
in increased production of adrenal androgens.
1. Hyperinsulinemia and IR  
Hyperinsulinemia is believed to be a biochemi-
cal, central and, probably hereditary alteration of
PCOS (Figure 4). In 1980, the association between
hyperandrogenism, insulin resistance and acanthosis
nigricans was identified (Hairan syndrome).16 Since
then IR has been the best biochemical correlation for
acanthosis nigricans.4
Insulin may act through insulin receptors,
which are distributed in the ovaries,44,45 through  IGF-
1 receptors or even by means of hybrid receptors that
contain a combination of α and β subunits of insulin
and IGF-1 receptors.46 Apparently there is a hereditary
genetic predisposition in post-receptor mechanisms
Hormones Ovaries Adrenal 
glands
Androstenedione  50% 50%
Total testosterone 5-20% 0-30%
DHEA 1-10% 90%
SDHEA 5% 95%
CHART 2: Percentage of androgen production by the
ovaries and adrenal glands
Sources: Spinedi E et al1, Perez Gutierrez JF et al3
LH
FSH
Ovary (thecal cell)
Ovary (granulosa cell) 
Estrone Estradiol
Inhibin
IGF
Insulin
Cholesterol
Progesterone
17OH-Progesterone17OH-pregnenolone
Androstenedione
5α reductase
Testosterone
aromatase aromatase
(SHBG, FT, Te-A)
Pregnenolone
DHEA
DHT
desmolase 3 β
17,20 3 β 17 α
17, 20
17 β−R 
17 β−R 
5 α−
R
 
17 α 3 β
AR - 
3α diol
peripheral
tissues
(+)
(-)
(+)
(-)
AdrenalCholesterol
Progesterone DOC       aldosterone
11 desoxycortisol
cortisol
OH-androstenedione
17OH-Progesterone17OH-pregnenolone
Androstenedione
Pregnenolone
DHEA
desmolase 3 β
17 α 3 β 17 α
11 β - 18
11 β− 
21
11 β− 17, 2017 α 3 β
SDHEA
17 β−R 17 β−R 
Testosterone
17-OH - 17 hydroxy, desoxycorticosterone acetate, 3β - 3β hydrox-
ysteroid dehydrogenase, T-A - albumin-bound testosterone, 11β -
11β hydroxylase, 17α - 17 hydroxylase, 17,20 - 17,20liase, 17β R -
17β reductase, DOC - desoxycorticosterone acetate,18 - 18 aldos-
terone synthetase, 21 - 21 hydroxylase 
In adrenal cortex, the androgens are precursors of glucocorti-
coid and mineralocorticoid synthesis, and their production is con-
trolled by ACTH (adrenocorticotropic hormone)30
LH receptors in the ovaries are found in thecal cells, corpus
luteum and stroma, whereas FSH receptors are in  granulosa
cells30
FIGURE 2: Steroidogenesis. Model of androgen
biosynthesis in the ovaries and adrenal glands
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Hypothalamus
secretion LH
secretion FSH
Ovary
Stimulus in stroma
and theca
Adipose tissue
Extraglandular
aromatization
Adrenal androgens
(normal plasma cortisol)
Chronic
anovulation Follicle matu-
ration
plasma FSH
plasma LHestrone
ACTH
Cortisol metabolism
5α reductase activity (liver) 11β HSD1activity (liver and
adipose tissue)
Obesity
Adrenal
Androgen excess 
ovarian androgen
secretion
FIGURE 3: Pathophysiology of PCOS
Source: American Association of Clinical Endocrinologists2, Rosenfield RL4, The Rotterdam ESHRE/ASRM et al9
Androgen excess in PCOS may be ovarian and/or adrenal and, consequently, increased biosynthesis of ovarian androgens results in
abnormalities in the whole hypothalamus-pituitary-ovary axis2,4,9
The peripheral increase in cortisol metabolism, due to impaired 5α-reductase and/or 11-beta hydroxylase activity, may lead to PCOS.49
However, in women with PCOS, the cause of this alteration remains unknown49
Abdominal obesity
Family hsitory of type 2 DM
Genetic predisposition - SOPC
Ageing 
Pregnancy
Drugs (corticosteroids, thiazide diuretics and danazole)
Way of life (physical deficiency of exercise, smoker)
Changes cholesterol
and lipoprotein meta-
bolism
PITUITARY
LH pulse and amplitude
PCOS
Free testosterone
estradiol
IGF-I 
SHBG
IGBP-I
Insulin resistance
hiperinsulinemia
Insulin receptor -           serine phosphorilation
Glucose transport
P450c-17
Androgen
alteration
OVARY
Androstenedione
Testosterone
ADRENAL
DHEA
SDHEA
In the pathogenesis of
hyperandrogenism of
PCOS, insulin may have a
direct and/or indirect mode
of action44,45
DM - diabetes mellitus,
P450c-17 - cytochrome, 11
HSD1 - 11 hydroxylase
PCOS therapy 
new target 
traditional target      
FIGURE 4: Peripheral insulin resistance and PCOS37
Sources: Kidson W37, Tsilchorozidou T49
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ble for the increased incidence of hypertension, coro-
nary artery disease and thrombosis in PCOS.57
2. Defect in the neuroendocrine system 
By and large, the inappropriate secretion of
gonadotropins is associated to the classical PCOS. The
increased secretion of gonadotropins is related to
increased activity of GnRH pulse generator and to pitui-
tary response to GnRH. LH and FSH synthesis and
secretion depend on GnRH stimulus, which is characte-
rized by fast and slow frequencies that, respectively,
favor their secretion.58 Deregulation of the mechanism
of GnRH secretion is still not clear. Through observa-
tions in the peripubertal period (adrenarche) in fema-
les, it was suggested that changes in neuronal system
information caused by insulin, IGFs (IGF1 and IGF2)
and sexual steroids could induce deregulation of GnRH
pulse generator.42,59 The weak peripheral aromatization
of the androgen from A and estrone concentration may
increase pituitary sensibility to GnRH by direct action in
the synthesis of gonadotropins, as well as sensibility of
GnRH receptors,60 thus contributing to pathogenesis of
PCOS and justifying the increased LH levels and the
excessive response of LH to GnRH. Marshall et al.58
observed some abnormalities in the function of hypo-
thalamic neurotransmitters.** However, it is still not
clear if these neurotransmitters play any role in the
pathophysiology of PCOS. In the polycystic ovary
syndrome, during the follicular phase, there is a dispro-
portion of gonadotropins, that is, LH pulsatile secretion
is increased and that of FSH is reduced.60 The increase
in the LH/FSH ratio*** from 2:1 to 3:1 indicates the
abnormal secretion of gonadotropins.61-63
3. Defect in ovarian steroid synthesis  
PCOS patients present an increase in GnRH28
and LH64 pulse frequency and, consequently, in ova-
rian androgen synthesis.28,29,49,64 It is still unknown if
increased GnRH pulse frequency is due to intrinsic
abnormalities in GnRH pulse generator or if it cau-
sed by relatively low levels of progesterone, resul-
ting in anovulatory cycles (Figure 3).28,29
Some studies carried out thecal cell cultures
suggest that these cells, in PCOS, are more efficient
to convert androgen precursors into T than the nor-
mal cells,29 and there is also deregulation in ovarian
steroidogenesis due to changes in the enzymes 17-
hydroxylase and 17, 29-lyase, that is, in cytochrome
of insulin, for many obese and insulin-resistant
women do not develop PCOS.19,46
The tyrosine-kinase insulin receptors include
IGF-1, epidermal growth factor, fibroblast growth
factor, platelet-derived growth factor, colony-stimu-
lating factor-1 and several cytokine receptors.18,19
The factor that induces phosphorylation of serin in
insulin receptor and in cytochrome P450-c17α
seems to be a protein-kinase, which causes IR and
hyperandrogenism, respectively. The factor respon-
sible for serin phosphorylation is genetically deter-
mined. Therefore, the genetic defect in serin phos-
phorylation could explain the association of PCOS
and IR.19,24 Hyperinsulinemia increases the produc-
tion of androgens in the ovaries and of IGFs in the
liver.37,39 The direct effect of insulin and IGF-1 is
increased 17-hydroxilase activity in the ovaries, cau-
sing an excessive production of androgens, particu-
larly A and T and its precursor, 17-hydroxyproges-
terone (17-OHP).46 IGF-1 inhibits the enzyme aroma-
tase and hence prevents the conversion of T into
estrogens.47 Indirectly,  insulin seems to potentialize
the action of LH in the ovaries.48 Another effect of
hyperinsulinemia, and similar to obesity, is to
decrease the hepatic production of SHBG, the pro-
tein that carries the sexual hormone sexual, and of
IGFBP-1, the protein that carries IGF-1 or IGF bin-
ding protein-1, thus contributing to a broader
action of free testosterone (FT) and IGF-1, respecti-
vely in target-cells.45,49
Glucose, leptin and lipid intolerance  
PCOS is a risk factor more important for gluco-
se intolerance than race ethinicity.24 The  association
between PCOS and gestational diabetes (type 1 and
2I) in families is controversial.50,51
Leptin* seems to have a direct effect in ovarian
steroidogenesis due to the  presence of leptin recep-
tors in thecal and granulose cells; moreover, granulo-
se cells are able to synthesize leptin (Figure 1A).52-54
Peripheral insulin resistance probably accounts for
reduction in leptin55 and resistin56 concentration in the
adipocytes of  women with PCOS. 
In PCOS, total cholesterol is increased because
of raised low-density lipoprotein (LDL); however,
high-density lipoprotein (HDL) is decreased. Blood
levels of triglycerids are elevated, as well as plasmino-
gen activator inhibitor (PAI). The increase in PAI lev-
els and alteration in lipid levels seem to be responsi-
* The obese individuals present leptin resistance.52, 53
** Dopamine, opioids and the alpha-adrenergic system.
*** The prevalence of increase in this ratio ranges from 30% to 90%. Such variability is due to the number and interval of samples collected
and to specificity of gonadotropins. The gene responsible for specificity is in LH b-subunit, and mutations in this subunit might be associat-
ed with gonadal dysfunction and infertility.61- 63
mode of inheritance is unknown. The several
genes4,19,29,30,40,42,43 proposed and investigated as the
main and possibly PCOS-related genes include those
that regulate the hypothalamus-pituitary-ovary
axis29,30,42,43 and those associated with peripheral insu-
lin resistance and its sequelae.4,19,40,41 New genes have
been identified and are related to insulin and gona-
dotropin action and secretion, and androgen bios-
ynthesis, secretion, transport and metabolism, contri-
buting to the heterogeneous phenotype of this syn-
drome.64,66,71
CLINICAL PICTURE AND DIAGNOSIS OF PCOS
The clinical picture (Chart 3) and the heteroge-
neous hormone profile, the multifactorial theory of its
pathogenesis and lack of consensus as to definition of
PCOS represent the factors that contribute to making
its diagnosis difficult. 
According to the last consensus,9 PCOS could be
diagnosed after ruling out other diseases that cause
irregular menstrual cycles and  androgen excess
(Figure 5, Chart 4), by means of identifying at least
two of the following criteria: oligo-ovulation or anovu-
lation, which is usually manifested with oligomenor-
rhea or amenorrhea; increased androgen levels in
blood (hyperandrogenemia) or clinical manifestations
of androgen excess (hyperandrogenism); and ovary
cysts defined by ultrasonography (10 or more cysts
measuring  2-8mm).9
PCOS is a chronic condition that has clinical
manifestations clinical at any age and not only in
P450c of thecal cells.28,30,49 Moreover, the synergic
effect of hyperinsulinemia and the increase in IGF
must be considered.48,49,65
In women suffering from PCOS, follistatin lev-
els are elevated and activin levels are lower than in
non-PCOS women.66
The peripheral metabolism of steroids is altered
in PCOS, primarily in adipose and muscular tissues
and in the pilosebaceous unit. Hence, hirsutism, acne,
seborrhea and  alopecia are common and reflect hype-
randrogenism, which may be progressive or not. 
The adipose tissue is able to form T and estro-
ne from inactive precursors,67 contributing to increa-
sed steroid levels. In the pilosebaceous unit, there is
an increase in activity of the enzyme 5α-reductase,
converting T into DHT.68,69 The activity of 5α-reduc-
tase is mediated by IGF-1 and may be intensified by
hyperinsulinemia, thus aggravating hirsutism.68,69
Insulin seems to have a  direct and stimulating effect
in the pilosebaceous unit (hirsutism, acne, seborrhea
and alopecia)4 and in the epidermis (acanthosis nigri-
cans).16
4. Peripheral increase in cortisol metabolism 
Increased androgen production by adrenal glands
is observed in 25% of PCOS patients,70 probably as a result
of genetic influence or secondary to abnormal secretion
of ovarian androgens.31,65
GENETICS OF PCOS  
PCOS is believed to be hereditary; however, the
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Intrauterine Children (peribuberal) Adolescents and adults Adults
(childbearing age): (postmenopausal):
Small baby syndrome Exaggerate adrenarche→ PCOS Metabolic syndrome: 
Intrauterine growth Premature pubarche Oligomenorrhea (85% to 90%) Cardiovascular disease, type 2
restriction ↑androgens or amenorrhea (30% to 40%), diabetes, obesity, 
↑insulin hirsutism* (92%), acne, endometrial hyperplasia
ovarian functional  seborrhea, alopecia, insulin endometrial cancer
hyperandrogenism - resistance (70%), metabolic 
hirsutism syndrome (30% to 40%),
obesity (30% to 40%), acanthosis 
nigricans, infertility (75%)
Controversies: bulimia, anxiety
and anorexia nervosa
CHART 3: Clinical manifestations of PCOS at different ages
Sources: Azziz R et al6, The Rotterdam ESHRE/ASRM et al9, Hull MG10, Burghen GA16, Urbanek M71
* Hirsutism severity and extension are clinically assessed by the Ferriman-Gallwey scoring system. This method is useful for diagnosing
hirsutism and following up the therapeutic response. The Ferriman-Gallwey system scores each body area from 0 (no hirsutism) to 4
(severe hirsutism). The diagnosis is consistent with a score higher than 8.
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factors.23,25,72
The complementary exams required for
PCOS investigation are basically ultrasound and
hormone levels.2,9,7
1. Ultrasonography 
It should be performed between day 25 of the
current menstrual cycle and day 3 of the next period.
Transvaginal, rather than abdominal, ultrasound is
recommended for providing better visualization.2,61
2. Hormones
General orientations  
a) Collect blood in the morning (8h), in the first
week of the regular menstrual cycle.**
Plasma hormone levels
a) 17-OHP - it is important to perform this test
women of childbearing age (Chart 3).71 The classical
form is characterized by high androgen, estrogen,
insulin and LH levels. The metabolic  syndrome
(Chart 5)9 in patients with PCOS, especially in pre-
menopausal women, is characterized by obesity, IR
and dyslipidemia. The increase in triglycerid and
total cholesterol levels, with elevated LDL and redu-
ced HDL,25,72 characterizes dyslipidemia. Hirsutism*
is the most frequent clinical feature  of hyperandro-
genism in skin and it may cause psychiatric disor-
ders in some patients. 
It is important to make an early diagnosis of
PCOS because of its association with high reproduc-
tive morbidity and increased risk of developing hor-
mone-dependent cancer, thus justifying a preventi-
ve treatment.23 Diabetes mellitus type 2, dyslipide-
mia, endometrial cancer, hypertension, cardiovas-
cular disease and ovary cancer are long-term risk
Two or three diagnostic criteria
Oligomenorrhea or amenorrhea 
Hyperandrogenism or hyperandrogenemia
Ultrasound with polycystic ovaries
Endocrine diseases that must be ruled out
1. Hyperprolactenemia 
2. Non-classical congenital adrenal hyperplasia
3. Cushing´s syndrome
4. Ovary neoplasms
5. Acromegaly
SOPC
17OHP, prolactin
in [17OHP]
da prolactin
Hyperprolactenemia
SDHEA,       DHEA
ACTH, FSH, LH, DHEA, SDHEA,
TI, 3α DiolG tests
slight         in
[17OHP] or
[normal]
SDHEA, normal DHEA,
3 α DiolG, FSH>3
Dexamethasone suppression test:
differential diagnosis between functional
and tumoral adrenal hyperandrogenism
FIGURE 5: Algorithm for diagnosis of PCOS
Fontes: American Association of Clinical Endocrinologists2, Ehrmann DA31
[ ] - levels
↑ − increase
The patients submitted to ACTH stimulation test may initiate on the day after the dexamethasone suppression test2
Interpretation of dexamethasone suppression test: a) Tt is suppressed by over 40% and SDHEA by over 60% - adrenal androgen, b)
Tt is suppressed by less than 40% - excess T is of adrenal and ovarian origin c) Tt is not suppressed, but SDHEA and cortisol are sup-
pressed - excess T is of ovarian origin. When there is a deficiency associated with androgen and cortisol secretion, the individual
probably suffers from adrenal hyperfunction (such as Cushing´s disease or adrenal cancer) or did not take dexamethasone as recom-
mended2
* Hirsutism is defined as the excessive growth of terminal hair in women, in characteristic anatomical areas, which are androgen-sensitive or
with a male distribution pattern. In hirsutism there is an excessive or inappropriate development and growth of the pilosebaceous unit. The
androgens cause transformation of vellus hair (which is fine, soft and non-pigmented) into terminal hair in androgen-sensitive areas.2,72
** Irregular menstrual cycles: random blood collection.
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Disease Hiperandrogenism and/  Oligomenorrhea Characteristics 
or hyperandrogenemia or amenorrhea
Clinical Hormone or
biochemical      
NCCAH (21- hydroxylase Yes Often absent Family history of ↑ basal 17-OHP level in 
deficiency) hirsutism and/or the morning or after 
infertility stimulation
Cushing's syndrome Yes Present Hypertension, striae ↑ cortisol in 24-hour
urine
Hyperprolactenemia No or moderate Present Galactorrhea  ↑ blood prolactin
or prolactinoma
Primary No or moderate May be Weakness, menstrual ↑ thyroid stimulating  
hypothyroidism present disturbances, xeroderma, hormone (TSH),
alopecia, weight gain  ↓ thyroxin (T4) 
and goiter prolactin level may 
be altered
Adrenal virilization  Yes Present ↑ clitóris, severe Extrem ↑ in blood
or ovarian neoplasm hirsutism, androge- androgen levels 
netic alopecia
CHART 4: Differential diagnosis of PCOS
Source: Ehrmann DA31
↑ - increase, ↓ - decrease.
Risk factor
Abdominal obesity (waist circumference) >88cm 
Triglycerids >150mg/dL 
HDL <50mg/dL
Blood pressure >130/>85mm Hg
Fasting glucose and glucose tolerance test (two hours), Fasting glucose =110-126mg/dL and/or
insulinemia  Glucose tolerance test (two hours) 
= 140-199mg/dL
Source: The Rotterdam ESHRE/ASRM et al9
 The analysis of only one criterion for IR should not be used for IR individuals73
 HDL - high density lipoprotein. Metabolic syndrome is confirmed by three or four criteria
Other insulin resistance indexes:
 Índice de Homa-b (homeostasis model Assesment): 20x insulinemia (µUI/ml)/glycemia (mmol/L) - 3,5
Normal range: 167 a 175.71,73 It evaluates β-cell secretory function74-76
 HOMA-r (Homeostasis Model Assesment): insulin (µUI/ml) x glycemia (mmol/L)/22,5. Normal range: 0,97-174-76
 Fasting glucose and insulin. Insulin resistance < 4,575
To change glycemia mg/dL into mmol/L: multiply by 0,05551.
CHART 5: Diagnostic criteria for metabolic syndrome
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z fasting glucose,
z body mass index (BMI), IR with BMI ≥
25kg m≈,
z glycemic index,
z glucose tolerance test - 2 hours after 75mg of
glucose, 
z fasting insulin - IR with insulinemia ≥ 17.3
UI/l in women, 
z fasting glucose/insulin ratio, 
z HOMA-r, 
z HOMA-b analysis 
k) as to lipid metabolism, it is recommended to
measure total cholesterol total and its fractions (HDL
and LDL) and triglycerids (Chart 5).2
TREATMENT
The choice of treatment in PCOS depends on
the clinical and laboratory pictures. In Dermatology,
the objective of treating PCOS is to reduce androgen
levels,* in order to attenuate their effects on skin
and pilosebaceous units.  Together with drug the-
rapy, it is necessary to change life style, diet and to
exercise.76
The therapeutical options for skin manifesta-
tions related to androgen excess include, as fol-
lows:
1. combined oral contraceptives: cyprote-
rone acetate (2mg) + ethinyl estradiol (35µg) for
21 days or drospirenone** (3mg) + ethinyl estra-
diol (30µg) for 28 days. The  antiandrogen effect is
due to decreased LH  and, consequently, reduced
ovarian production of androgen by the estrogenic
component.2 Estrogens also increase the synthesis
of SHBG, thus reducing FT.2 The use of oral contra-
ceptives requires special monitoring, that is, gyne-
cologic and breast examination.2 The effectiveness
of contraceptives is greater in acne (50%) and
lower in hirsutism, which requires administration
for longer periods.2,31,77 The adverse effects of con-
traceptives in IR, glucose tolerance, vascular reacti-
vity and coagulability should be taken into
account, particularly after availability of drugs that
reduce insulin levels.78
2. antiandrogens: a) cyproterone acetate
(25mg to 50mg, in the first 10 days of the cycle) - it
is a potent progesterone with moderate antiandro-
gen action. It inhibits T and DHT binding to andro-
gen receptor, reduces the concentration of  5α-
reductase in the skin and decreases the secretion of
in the morning because of corticotropin peak. In
PCOS, 17-OHP levels may be normal or slightly
increased.31 The plasma prolactin and 17-OHP levels
are enough to rule out hyperprolactenemia and
NCCAH due to 21-hydroxylase deficiency. 
b) Prolactin - normal levels.31
c) FSH and LH - LH/FSH ratio is > 3:1.61
d) TT, FT and SHBG - the method recom-
mended9 to calculate FT is by measuring TT and
SHBG levels. FT levels are increased and SHBG lev-
els are reduced. TT levels may be elevated or nor-
mal.2,9
e) Dehydroepiandrosterone DHEA and SDHEA
- both in PCOS and NCCAH, the increase in SDHEA
levels is  lower than 7 µg/dL. In adrenal tumors,
SDHEA is higher than 7µg/dL. DHEA is increased in
NCCAH (Chart 2).2
f) 3-alfa diol G - it is a DHT metabolite pro-
duced in androgen-responsive tissues (for instan-
ce, hair follicle). It is raised in PCOS, idiopathic
hirsutism and it is decreased in 5α-reductase deff-
ciency.2
g) Adrenocorticotropic hormone  (ACTH) sti-
mulation test. Cortrosyn® - 250ug IV- the test is
performed to detect deficiency of several steroido-
genesis enzymes in adrenal glands, mainly 21-
hydroxylase deficiency.2 The test is indicated only
for screening morning levels of 17-OHP with above
normal concentrations or if there is any suspicion
of enzyme deficiency. Plasma cortisol, 17-OHP,
SDHEA and DHEA should be measured in the mor-
ning, before and 60 minutes after Cortrosyn®
injection.2
h) GnRH stimulation test - it is conducted to
confirm the ovarian origin of androgens. In PCOS
investigation it is useful to identify the presence of 17-
hydroxylase deficiency.2
i) Dexamethasone suppression test (Figure 5) -
it is performed to differentiate  functional adrenal
hyperandrogenism (ACTH-dependent) from tumoral
adrenal hyperandrogenism (ACTH-independent). The
test is indicated when TT is higher than 200ng/mL,
and/or SDHEA is higher than 7µg/dL. Plasma cortisol,
SDHEA and TT should be measured in the morning
before and five days after the administration of dexa-
methasone (0.5mg, four times/day, at 6, 12, 18 and 24
hours).2,*
j) IR - several criteria have been suggested to
assess IR (Chart 5):72-75
* The decrease in androgen levels may occur by inhibiting its production in the ovaries, by increased SHBG levels or blocking receptors in
target tissues.
** Drospirenone is a spironolactone analogue.
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ovarian androgens by inhibiting gonadotrofin
release.2 Hirsutism improves after a 3-to-6-month
treatment.77 The side effects include irregular uteri-
ne bleeding, nausea, vomiting, headache, fatigue,
weight gain and reduced libido.2,79
b) spironolactone - it has a moderate
antiandrogen effect when administered as a 100-
200mg/day dose. Shaw80 published the following
guidelines for spirolanoctone: initial dose of
25mg, twice a day; if well tolerated, increase to
50mg, twice a day; in case of no benefits after
three months, higher doses should be consid-
ered. The duration of treatment could be exten-
ded and associated with combined oral contra-
ceptives.
c) flutamide - potent nonsteroidal antian-
drogen that is effective in treating hirsutism, but
severe hepatocellular dysfunction has limited its
use.31
d) finasteride - It is a 5α-reductase inhibitor that
is given for hirsutism, 5mg/day, and patients improve
after three-months81
d) eflornithine - inhibitor of the enzyme decar-
boxylase ornithine in human skin, it is available in
creams for topical use. The primary action of the drug
is to inhibit hair growth.82
3. insulin-sensitizing agents: metformin, thi-
azolidinedione.31,78 These agents enhance tissue sensi-
tization to the action of insulin. 
a) metformin* - Velásquez83 published the
first study on metformin in PCOS. Metformin
reduces hepatic gluconeogenesis and increases
muscle sensitization to insulin, decreasing serum
insulin levels and thus reducing androgen produc-
tion by thecal cells.84 However, it is not a hypogly-
cemic agent because it does not increase insulin
secretion.2,85 Moreover, metformin reduces total
cholesterol, LDH and triglycerid levels, and increa-
ses HDL levels.86,87 Decreased androgen concentra-
tion caused by metformin is an effect still not
clear.84 Apparently it has direct influence in ova-
rian steroidogensis, reducing androgen produc-
tion.84 The recommended dose is 500mg, 3x/day or
850mg, 3x/day. It is effective in treating anovula-
tion in women with PCOS and, in long-term treat-
ments it may improve hirsutism.87 The most impor-
tant side effects are gastrointestinal symptoms
(diarrhea, nausea, vomiting, flatulence and anore-
xia), which occur in 30% of patients, decreased
B12 vitamin levels in 6% to 9%, and metallic taste
in 3%. The contraindications are renal disease,
metabolic acidosis, congestive heart failure, and
hypersensitiveness to metformin. Avoid use of
contrast medium containing iodine.2,83,84
b) thiazolidinediones (troglitazone, pioglita-
zone, rosiglitazone) - these are true insulin-sensitiz-
ing agents that are able to improve insulin action in
the liver, skeletal muscles and adipose tissue.85,86
These drugs have the capacity to activate certain
genes involved in fat synthesis in carbohydrate
metabolism, thus improving IR, hyperandrogenemia
and glucose tolerance,85-87 and they lead to less
weight loss than other insulin-sensitizing agents.88
Roziglitazone and pioglitazone are currently appro-
ved for use. Treatment with roziglitazone was asso-
ciated with improved function of pancreatic β-cells
and decrease in PAI.85,86
c) D-chiro-inositol - it was recently studied in
PCOS patients. It is a pure substance called pinitol,**
derived from pine trees.89 The therapy with D-chiro-
inositol, in obese women with PCOS improves insu-
lin metabolism by acting in its receptors, decreasing
serum insulin and androgen (FT and increased
SHBG) levels.86,89 The recommended dose is
1200mg/day.85
The response to therapy with insulin-sensitiz-
ing agents is directly proportional to BMI, fasting insu-
lin, total cholesterol and LDL-cholesterol and blood
pressure, and inversely proportional to A and HDL
levels.
CONCLUSION
PCOS is a complex disorder of unknown
etiology, and it involves several specialists for pre-
senting reproductive, endocrinologic, dermatolo-
gical, gynecological, cardiac and psychological
implications. 
Hyperinsulinemia seems to be one of the
main factors responsible for steroidogenesis dereg-
ulation.  
The variable and heterogeneous clinical pictu-
re makes diagnosis of PCOS difficult and tends to
delay management that could avoid late complica-
tions.  
Its treatment is preventive and aims to main-
tain the endometrial healthy, to antagonize the
actions of androgens in target-tissues, to reduce
insulin resistance (IR) and to correct anovulation.
In addition to combined contraceptives and antian-
drogens, the insulin-sensitizing agents are effective
in preventing diseases associated with hyperinsu-
linemia. It is difficult to explain the therapeutic
* It is a biguanide molecule.
** This drug is chemically defined as inositol.
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specialists share investigations, trying to understand
the etiology and pathophysiology of PCOS, which are
essential for its treatment. The main focus of these
studies has been several genetic and environmental
determinants of the syndrome, for reflecting its hete-
rogeneous phenotype. 
success of metformin in reducing insulin and
androgen levels, as observed in some studies. It
may be related to genetic variations, body weight,
life style, duration of treatment and dosage of the
drug.
Today, in order to avoid late complications, the
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